UF Department of Psychiatry

Teresa A. Pigott, M.D.

Professor

Dr. Pigott joined the faculty in June 2001 as a Professor and Director of the Clinical Trials Division. Prior to that Dr. Pigott served as the Director of Clinical Trials Research at UTMB, Galveston and as the Chief of Psychopharmacology Research Division at Georgetown University. A 1984 graduate of Northeastern Ohio Universities College of Medicine (NEOUCOM), Dr. Pigott completed her residency in general psychiatry at MUSC, Charleston. She went on to complete a fellowship in Psychopharmacology in the Division of Intramural Research, National Institute of Mental Health. Following her fellowship, she continued at NIMH as Chief of the Adult Obsessive-Compulsive Disorder (OCD) Research Studies Unit and as a Senior Clinical Investigator in Clinical Neuropharmacology.

Dr. Pigott's research has been in the area of anxiety disorders, particularly concerning the pathophysiology and pharmacological treatment of OCD. She has continued to be an active and productive clinician, researcher and thought leader in Neuropharmacology and Clinical Trials with over 60 publications, 70 abstracts, and 200 presentations. She routinely serves on various regional, national and international Scientific Advisory Boards concerning clinical trials development and design.

Dr. Pigott has also distinguished herself as an outstanding and effective educator at the undergraduate, graduate and postgraduate levels. She has received numerous awards and recognition for her skill as a teacher and is a highly sought after presenter at the national and international level. She is often cited by her students and trainees as an outstanding role model and mentor most notable for her enthusiasm, depth of knowledge, and character.

Clinical Interests

Dr. Pigott's clinical interests are primarily in the area of the pharmacological treatment of patients with affective, anxiety, and/or psychotic disorders. She also has extensive clinical experience in the treatment of patients with eating disorders. She also has extensive clinical experience in performing psychiatric evaluations and consultations for patients in primary care settings.

Research Interests and Scholarly Interests

Most of Dr. Pigott's research has been in the area of anxiety disorders, particularly concerning the pathophysiology and pharmacological treatment of obsessive-compulsive disorder (OCD). She has recently started to conduct clinical treatment trials in the area of affective and/or psychotic disorders. She has also recently started to investigate the impact of gender on the presentation and treatment of patients with anxiety disorders. The Department has had a well-established Clinical Trial Program since 1993, but Dr. Pigott expects to further enhance our clinical trial activities by expanding into the inpatient sector.

Educational Interests and Accomplishments

Dr. Pigott has always been very interested in the training of medical students and residents. As a result, she has been an enthusiastic participant in education-related activities including didactics, case conferences, direct trainee supervision, and she has served on various education-related committees (Medical School Admissions Committee, Residency Training Committee, etc.). She served as the primary instructor for the Behavioral Medicine Course for Family Medicine Residents at UTMB; the UTMB Family Medicine Department provided 10% salary support for of these duties. She also developed, directed, and funded the first Psychopharmacology Fellowship for PGY-5 Psychiatry residents at UTMB. Currently she is directing the Psychopharmacology Course for our PGY-2 Psychiatry Residents.

Leadership And Service

Dr. Pigott is currently directing our Clinical Trial Division, which is comprised of 4 other Principal Investigators, 4 full-time study coordinators (R.N.s), and 4 additional support staff positions. She routinely serves on various national and regional Scientific Advisory Boards and other forums for "Opinion Leaders" concerning psychiatric treatment issues.

Publications (since 1997)

Broocks A, Briggs NC, Pigott TA, Hill JL, Canter SK, Tolliver TJ, Baldemore D, Murphy DL. Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-CPP with and without ondansetron pretreatment. Psychopharmacol. 130: 91-103, 1997.

Pigott TA, Seay S.. Pharmacotherapy of OCD. International Rev Psychiatry. 9: 133-147, 1997.

Broocks A, Pigott TA, Hill JL, Canter S, Grady TA, L'Heureux F, Murphy DL. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. Psychiatry-Res. 79(1): 11-20, 1998.

Pigott T. Obsessive-compulsive disorder: Symptom overview and epidemiology. Bulletin of the Menninger Clinic 62(4) A: A4-A32, 1998.

Pigott T, Seay S.. A Review of the Efficacy of Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder. J. Clin. Psychiatry 60(2): 101-106, 1999.

Crimson ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RMA, Kahn DA, Da Battista C, Nelson JC, Nierenberg AA, Sackeim HA, Thase ME. Texas Consensus Conference Panel: The Texas Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry. 60(3): 142-156, 1999.

Altemus M, Jacobson KR, Debellis M, Kling M, Pigott T, Murphy DL, Gold PW. Normal CSF oxytocin and NPY levels in OCD. Biol-Psychiatry. 45(7): 931-3, 1999.

Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SP, Suppes T, Miller AL, Trivedi MH, Swann AC, Biggs MM, Shores-Wilson K, Kashner TM, Pigott T, Chiles JA, Gilbert DA, Altshuler KZ. Medical Treatment for the Severely and Persistently Mentally Ill: The Texas Medication Algorithm Project. J Clin Psychiatry 60(5): 284-291, 1999.

Pigott TA. Gender differences in the epidemiology and treatment of anxiety disorders. J Clin Psychiatry 1999;60 Suppl 18:4-15. Steketee G, Pigott TA. Obsessive-Compulsive Disorder: The Latest Assessment and Treatment Strategies. Kansas City, MO.: Compact Clinicals, 1999.

Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, Greist JH, Holland D, McConville BJ, Pigott T, Walkup JT. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001 Feb;40(2):222-9.

Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG; Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003 Sep;64(9):1048-56.

Cloitre M, Yonkers KA, Pearlstein T, Altemus M, Davidson KW, Pigott TA, Shear MK, Pine D, Ross J, Howell H, Brogan K, Rieckmann N, Clemow L. Women and anxiety disorders: implications for diagnosis and treatment. CNS Spectr. 2004 Sep;9(9 Suppl 8):1-16.

Pigott TA. Anxiety disorders in women. Psychiatr Clin North Am. 2003 Sep;26(3):621-72, vi-vii.

Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin. 2007 Apr 27; [Epub ahead of print]

Last updated on